In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
Both drugs mimic GLP-1, increase insulin secretion, and slow gastric emptying
The primary mechanism involves stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, and slowing gastric emptying
I didnt recognize myself in the mirror
This pairs really well with your earlier diabetes tools nice to see these features building on each other.